Chronic kidney disease (CKD) in clinical is defined as a gradual loss of kidney function for more than 3 months. The pathologic course of CKD is characterized by extensive renal fibrosis; thus, preventing renal fibrosis is vital for the treatment of CKD. It has been reported that microRNA (miR)-374a-5p was under-expressed in renal venous blood samples from patients with CKD. In addition, it exhibited anti-apoptotic effects in renal tissues suggesting that miR-374a-5p may play an...

Sustained cardiac hypertrophy (CH) contributes to many heart diseases. Long noncoding RNAs (lncRNAs) collectively play critical roles in cardiovascular diseases (CVDs). However, the roles of lncRNA H19 in CH are still unclear. A CH model was constructed utilizing isoproterenol (ISO). We demonstrated H19 could participate in regulating ISO-induced CH development both in vivo and in vitro. The online databases DIANA and TargetScan were used to predict the targets of H19 and MicroRNA-145-3p (miR-145-3p), respectively. Luciferase...

Triggering receptor expressed on myeloid cells 1 (TREM1) participates in the development of endometritis. This study aims at identifying the effects and interaction of TREM1 and upstream stimulatory factor 2 (USF2) in endometritis by using a model of lipopolysaccharide (LPS)-induced human endometrial epithelial cells (HEnEpCs). ELISA was performed to determine the levels of interleukin (IL)-6, IL-1β, and tumor necrosis factor (TNF-α) after LPS stimulation. TREM1 and USF2 expression was examined with RT-qPCR and Western blot....

Additional file 1: Figure S1. Panx 2 and Panx 3 mRNA expression after CCI. A-B. A qPCR assay was used to detect Panx 2 (A) and Panx 3 (B) mRNA levels at 4 and 14 days post-CCI. The data are mean ± SEM. n = 3 mice/group. **p < 0.01, ***p < 0.001, vs. sham injury. The data were analyzed by one-way ANOVA followed by Dunnett’s test.

Additional file 2: Figure S2. The distribution of Panx 1 in the DRG and within sciatic nerves. A. Double-immunofluorescence images of Panx 1 (green) and the sciatic nerve axonal marker, NF200 (red). (B). Images of Panx 1 immunostaining (red) and, Nissl staining (green) in the DRG; Scale bar = 50 μm. Enlarged images in lower panel are from the inset boxes of upper panel. Upper panel, scale bar = 100 μm. Lower panel, scale bar...

Additional file 1. Figure S1. (A) Sequences of different mutations in G1 from G0 (germinal mutations occurred in these G0 individuals). The top sequence represented wild type. The target sequences were in bold and PAM sequences (CGG) was highlighted with red. Expected cut sites were marked by a red triangle. Among these mutations, deletions were indicated by dotted lines and insertions by red lower case letters. (B) Phenotypes of homozygous mutant (Orco-/-) and wild type...

Additional file 1. Figure S1. (A) Sequences of different mutations in G1 from G0 (germinal mutations occurred in these G0 individuals). The top sequence represented wild type. The target sequences were in bold and PAM sequences (CGG) was highlighted with red. Expected cut sites were marked by a red triangle. Among these mutations, deletions were indicated by dotted lines and insertions by red lower case letters. (B) Phenotypes of homozygous mutant (Orco-/-) and wild type...

Additional file 8. Figure S8: MSA-2 combined with YM101 therapy promoted immunity-associated gene expression in B16 model. The heatmaps showing the change folds of genes constituting immune signatures.

Additional file 9. Figure S9: The effect of the combination therapy on proliferation and apoptosis markers in B16 and EMT-6 model. (a) Tunel staining in B16 model. (b) Ki67 staining in B16 model. (c) Tunel staining in EMT-6 model. (d) Ki67 staining in EMT-6 model. (e) PCNA staining in EMT-6 model.

Additional file 3: Figure S3. Analysis of blood physiology parameters of control, vehicle- and CurE-treated mice. The following blood physiology functions were assayed: WBC: white blood cell count; RBC: red blood cell count; HGB: hemoglobin; MCV: mean corpuscular volume; RDW: red blood cell volume distribution width; PLT: platelet; LYM: lymphocyte count; MON: monocyte count; NEUT: neutrophil count. The data were shown as mean ± standard deviation. N = 6 for each group, **P < 0.01...

Additional file 5: Figure S5. Overexpression of CDK1 enhanced protein stabilities of UBE2C and AURKA/B. a Expressions of UBE2C and AURKA/B in SW-13_NC and SW-13_CDK1 cells after treatment with CHX (100 μmol/L) at 0, 1, 3, 9, 12 h. b Relative expression of UBE2C, AURKA c and AURKB d in SW-13_NC and SW-13_CDK1 cells after treatment with CHX. Statistical differences were assessed by two-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001.

Additional file 5: Figure S5. Overexpression of CDK1 enhanced protein stabilities of UBE2C and AURKA/B. a Expressions of UBE2C and AURKA/B in SW-13_NC and SW-13_CDK1 cells after treatment with CHX (100 μmol/L) at 0, 1, 3, 9, 12 h. b Relative expression of UBE2C, AURKA c and AURKB d in SW-13_NC and SW-13_CDK1 cells after treatment with CHX. Statistical differences were assessed by two-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001.

Additional file 6: Figure S6. Silencing the markers of apoptosis or pyroptosis could not rescue CurE-mediated cell death. a Transfection efficacy of knockdown caspase 3 expression in SW-13 cells. b Transfection efficacy of knockdown caspase 3 expression in NCI-H295R cells. c Transfection efficacy of knockdown GSDMD expression in SW-13 cells. b Transfection efficacy of knockdown GSDMD expression in NCI-H295R cells. e Silencing caspase 3 increased necrotic cells triggered by CurE in SW-13 cells. f Silencing...

Additional file 2.

Additional file 3.

Additional file 5. Figure S3. Summary of the recorded sensilla types according to the response profiles [50] in wild type (n = 72) (A) and homozygous mutant males (n = 70) (B). Type A sensilla only responded to Z11-16: Ald, while type B sensilla responded to Z9-14: Ald. Sensilla responding to Z9-16: Ald and Z9-14: Ald were classified as type C. The remaining sensilla were considered as “others” in pie chart.

Additional file 9. Figure S5. Setup for behavioral tracing of a larva in a dual-choice arena system.

Additional file 7: Supplementary Figure 3. A Silver staining of the complexes precipitated by the biotinylated circZNF451/NC probe. The red arrow marks the specific band of the circZNF451 probe. B The overlap of the mass spectrometry data, the predicted candidates for circZNF451 in circInteractome and the most detected binding motifs for circZNF451 in catRAPID database. C After coculturing with H1395/H1975-shcircZNF451 and GW4869 (20μM), FXR1 expression in macrophages was detected via western blotting. D and E...

Additional file 2: Figure S2. Raw western blots of GFAP (a), C3d (b), S100a10(c) and β-actin (d) in Figure 4b 12% Gel, 0.45 µm PVDF membrane.

Additional file 5: Figure S5. Raw western blots of GFAP(a), C3d (b), S100a10(c) and β-actin (d) in Figure 7c 12%Gel, 0.45 µm PVDF membrane.

Additional file 1: Fig. S1. DNA methylation level trends. (A) Bean plots showing the methylation level distribution of methylation sites in the context of CpG, CHG and CHH at genome wide scale. (B) The methylation level trends around gene features per sample. a = promoter (2 kb upstream of transcription start site); b = first exon; c = first intron; d = inner exons; e = inner introns; f = last exon; g = downstream...

Additional file 2: Fig. S2. Methylation status of differentially methylated sites. (A-B) Volcano plots showing DMCs in the context of CHG (A) and CHH (B). (C) Bar plots showing distribution of differences in methylation levels of DMCs.

Additional file 4: Fig. S4. DNA methylation landscape. (A) The number of DMCs grouped by the differences in methylation levels per chromosome. (B-D) Manhattan plots showing the global distribution of DMCs in the context of CpG (B), CHG (C) and CHH (D). (E) DNA methylation landscape of chromosome 2.

Additional file 2: Fig. S2. The pooled incidences of local control at 1, 2, 3, 4, 5 and 10 years after C-ion RT for chondrosarcoma.

Additional file 4:Fig. S4. The pooled incidences of overall survival at 3, 5 and 10 years after C-ion RT for chordoma.